• CBD insomnia trial recruiting remaining patients in early 2026 for interim analysis
• $2.5 million raised to accelerate commercial manufacturing for CBD insomnia product
• Cash balance as at 31 December 2025 was $4.7M with an estimated $1.8M in R&D tax credits forecast for Q2 2026
• Patent allowances secured for CBD soft-gel formulation in the US and Europe

Avecho Biotechnology Limited (ASX: AVE) has presented its Quarterly Activities Report and Appendix 4C for the quarter ended 31 December 2025. The company reported continued progress in recruitment for the interim analysis cohort of its pivotal Phase III clinical trial evaluating its CBD TPM® soft-gel capsule for the treatment of insomnia. As of 18 December 2025, a total of 190 patients had been dosed, representing the majority of the approximately 210 participants required for the planned interim analysis. Recruitment has continued into early 2026 to enrol the remaining participants. Avecho also announced that it had secured $2.5 million in funding via a placement to accelerate commercial manufacturing activities required to support a future TGA submission and commercial supply of its lead CBD TPM® soft-gel capsule for insomnia. The company reported a cash balance of $4.7 million as at 31 December 2025, with an estimated $1.8 million in R&D tax credits forecast for Q2 2026. Additionally, Avecho announced that the United States Patent and Trademark Office and the European Patent Office have allowed its patent applications covering the company's proprietary CBD TPM® soft-gel capsule, which is currently in Phase III clinical development for the treatment of insomnia.

The company reported a cash balance of $4.7 million as at 31 December 2025, with an estimated $1.8 million in R&D tax credits forecast for Q2 2026.